Info

Boston Life Sciences, Inc (NASDAQ: BLSI) is a biotechnology company engaged in the research and development of biopharmaceutical products for the diagnosis and treatment of Central Nervous System disorders. Our energy and focus in this area are reflected in several important initiatives. Our molecular imaging program has a product candidate, the ALTROPANE® molecular imaging agent, in phase 3 clinical development. ALTROPANE® is a diagnostic tool intended to aid in differentiating Parkinsonian tremors from non-Parkinsonian or Essential Tremor. ALTROPANE is also being assessed in Phase II trials for diagnosing ADHD. Through our licensing and research collaboration with Children's Hospital Boston, Boston Life Sciences maintains a world-class position in the field of regenerating nerve axons. Our sponsored scientific research in this ground-breaking technology may someday make possible therapies leading to functional recovery following stroke, spinal cord and ocular injuries. Finally, our program in Parkinson's Disease aims to provide a therapeutic solution to managing the symptoms as well as to slowing the progression of the disease.